Regeneus Ltd (RGS:ASX)


right-arrow Created with Sketch. -0.015 (-13.04%)
MCAP $30.02M
Last trade 16.10pm 07/05/2021 20mins delayed

Latest Announcements

07/05/2021RGSRegeneus Ltd
07/05/2021 Price SensitivePSRGSRegeneus Ltd
05/05/2021RGSRegeneus Ltd
30/04/2021 Price SensitivePSRGSRegeneus Ltd
29/04/2021 Price SensitivePSRGSRegeneus Ltd
16/03/2021 Price SensitivePSRGSRegeneus Ltd
03/03/2021 Price SensitivePSRGSRegeneus Ltd

Company Overview

Regeneus Ltd is a clinical-stage regenerative medicine company. The Company is engaged in developing cell-based therapies for human and animal health markets, with a focus on osteoarthritis and musculoskeletal disorders, as well as oncology and dermatology diseases. The Company's portfolio of therapeutic products is being developed using stem cell and immune oncology technology platforms. The Company's technology platform includes approximately three platforms across both human and animal health businesses, including Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases; Human and animal immunotherapy personalized cancer vaccine for the treatment of various cancers, and Stem cell secretions cell free supernatant (CFS) technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments. The Company's products include Kvax, CryoShot, Progenza, Human Cancer Vaccine and Secretions Cream.

RGS in the news

Search Previous Announcements